Understanding Cernitin (Cernilton) and its Positive Effects on Sexual Health and Prostate Strength
Cernitin™ extract (sometimes referred to its generic name, cernilton) is derived from the pollen of a variety of types of plants. Cernitin is gathered in the fields and combined in standardized proportions. In the U.S., the exclusive manufacturer of Cernitin is Graminex, which works with its European partners to support clinical research on the Cernitin compound.
There are a number of active substances in Cernitin extract. It is made through a special process from Cernitin flower pollen. There are two specific fractions isolated in the Cernitin extraction process. T60™ is the hydrophilic, water-soluble fraction, and GBX™ is a lipophilic, fat-soluble fraction, which contains natural rancidity inhibitors. Together, these fractions extracted from Cernitin contain a range of compounds including vitamins, amino acids, nucleic acids, minerals, long chain alcohols, unsaturated fatty acids, prostaglandin precursors, enzymes, plant hormones and more.
Clinical Research on Cernitin/cernilton
Clinical research has looked at Cernitin for conditions including immune function and liver support. The primary research on Cernitin, however, has looked at its effect on prostatitis. This condition involves chronic prostate inflammation not related to conditions such as muscle strain, trauma or infection. Cernitin has been used in the treatment of chronic prostatitis for nearly 30 years with favorable results.
One study, published in 1989, reported that researchers gave Cernitin extract to 15 patients, ranging in age from 23 to 63 years and who were diagnosed with chronic prostatitis or prostatodynia. Duration of treatment varied from one to 18 months, in which time seven patients became symptom-free, six significantly improved and two failed to respond. Two patients had a recurrence of symptoms after cessation of Cernitin treatment, which were cleared up when recommencing treatment.
Researchers concluded that Cernitin was "effective in the treatment of chronic prostatitis and prostatodynia. Its precise mode of action is not known, although experimental studies suggest that Cernitin has anti-inflammatory and antiandrogenic properties."
Cernitin is effective in the treatment of chronic prostatitis and prostatodynia.
A more recent study on Cernitin and prostatitis was published in the peer-reviewed journal, The Prostate, in 2001. Researchers hoped to assess the mechanisms of the anti-prostatitis effect of Cernitin extract through studying the mode of action in a nonbacterial prostatitis rat model. Rats were administered estradiol after castration, which resulted in similar histologic conditions as human prostatitis. Treatments began at 17 days into the 31-day experiment; at the end of the experiment, researchers concluded that Cernitin "can work as a potent anti-inflammatory agent against chronic prostatitis.
While the majority of research studies have focused on Cernitin's effect on prostatitis, other clinicals have looked at how it protects the liver from hepatotoxins and may have some role in protecting the body from cancer. In one study, researchers found that Cernitin extract protected the livers of rats from toxic actions of ethionine or galactosamine. Another study explored what compound may be responsible for the ability of Cernitin to inhibit the growth of some prostate cancer cells.
See a detailed listing of clinical trials and studies concerning Cernitin and flower pollen extracts.
- Denis, L. "Chronic prostatitis." Acta Urol Belg 34:49-56, 1966.
- Saito, Y. "Diagnosis and treatment of chronic prostatitis." Clin Exp Med 44:2-15, 1967.
- Buck, AC, et al. "Treatment of Chronic Prostatitis and Prostatodynia with Pollen Extract." Brit J Urol 64:496-499, 1989.
- Kamijo, T, et al. "Effect of Cernitin Pollen-Extract on Experimental Nonbacterial Prostatitis in Rats." Prostate 49:122-131, 2001.
- Samochowiec, L, and Wojcicki, J. "The effect of pollen on the changes in the liver of laboratory rats evoked by ethionine, carbon tetrachloride, allyl alcohol and galactosamine." Arch Exp Veterinarmed 43(4):521-32, 1989.
- Roberts, KP, et al. "Cyclic hydroxamic acid inhibitors of prostate cancer cell growth." Prostate 34(2):92-9, 1998.